FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

Petition Seeks Ban on Music in DTC Ads

A citizen petition asks FDA to ban music in direct-to-consumer television, radio and internet streamed advertisements because it distracts the audienc...

Human Drugs

Content/Process Guide for Pediatric Study Plans

FDA posts a final guidance on content and submission process for pediatric study plans.

Human Drugs

Janssen sNDA for Spravato OKd for Major Depression

FDA approves a Janssen Pharmaceutical supplemental NDA for Spravato (esketamine) nasal spray, taken with an oral antidepressant, to treat depressive s...

FDA General

Since Our Last Issue ...

Industry news you may have missed since our last issue.

Federal Register

Submission Data Elements for Imported Vet Devices

Federal Register proposed rule: FDA proposes to amend its regulations to require that certain data elements be submitted for veterinary devices that a...

Federal Register

FDA Withdraws Watson Generic Oxycodone/Ibuprofen

Federal Register notice: FDA withdraws approval of a Watson Pharmaceutical ANDA for oxycodone hydrochloride and ibuprofen tablets, indicated for relie...

Human Drugs

Genentech Triple Combo OKd for Melanoma

FDA approves a Genentech supplemental BLA for its triple combination of Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib...

Federal Register

FDA Adds 4 APIs to Compounding List

Federal Register notice: FDA identifies four drug substances to be added to its list of bulk drug substances (active pharmaceutical ingredients) for w...

Biologics

BMS/Bluebird Resubmit BLA for Multiple Myeloma

Bristol Myers Squibb and Bluebird Bio re-file their BLA for idecabtagene vicleucel, indicated for treating patients with heavily pre-treated relapsed ...

Human Drugs

Catalyst Loses NDA Lawsuit Against FDA

Catalyst Pharmaceuticals loses against FDA in a lawsuit over the agency's approval of competitor Jacobus Pharmaceuticals Ruzurgi (amifampridine).